Filter

Tumor Types

Investigational Therapies

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Showing results

Phase III

BREAST

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

BREAST

Inavolisib
(PI3K alpha inhibitor)

(RG6114)

BREAST

Giredestrant (SERD)

(GDC-9545, RG6171)

BREAST

GASTROINTESTINAL

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)g

GASTROINTESTINAL

GENITOURINARY

Tiragolumab
(anti-TIGIT)

(MTIG7192A, RG6058)

GASTROINTESTINAL

LUNG

GENITOURINARY

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)

GASTROINTESTINAL

GENITOURINARY

GYNECOLOGIC

HEAD/NECK

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)g

GASTROINTESTINAL

GENITOURINARY

HEAD AND NECK

HEMATOLOGY

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)c

HEMATOLOGY

LUNG

Tiragolumab
(anti-TIGIT)

(MTIG7192A, RG6058)

GASTROINTESTINAL

LUNG

MELANOMA

PAN TUMOR

SOLID TUMOR

Phase II

BREAST

Giredestrant (SERD)

(GDC-9545, RG6171)

BREAST

GASTROINTESTINAL

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)g

GASTROINTESTINAL

GYNECOLOGIC

SOLID TUMOR

GENITOURINARY

GYNECOLOGIC

Tiragolumab
(anti-TIGIT)

(MTIG7192A, RG6058)

GYNECOLOGIC

LUNG

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)g

GASTROINTESTINAL

GYNECOLOGIC

SOLID TUMOR

HEAD/NECK

HEMATOLOGY

Mosunetuzumab
(CD20 x CD3)

(RG7828)

HEMATOLOGY

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)c

HEMATOLOGY

LUNG

MELANOMA

Autogene cevumeran (iNeST)

(RG6180)f

MELANOMA

SOLID TUMOR

PAN TUMOR

SOLID TUMOR

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)g

GASTROINTESTINAL

GYNECOLOGIC

SOLID TUMOR

Autogene cevumeran (iNeST)

(RG6180)f

MELANOMA

SOLID TUMOR

Pralsetinib
(RET inhibitor)

(RG6396)

SOLID TUMOR

Phase I

BREAST

HER2 x CD3

(RG6194)

BREAST

GASTROINTESTINAL

SOLID TUMOR

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

BREAST

Giredestrant (SERD)

(GDC-9545, RG6171)

BREAST

Inavolisib
(PI3K alpha inhibitor)

(RG6114)

BREAST

SOLID TUMOR

Tiragolumab
(anti-TIGIT)

(MTIG7192A, RG6058)

BREAST

SOLID TUMOR

HEMATOLOGY

GASTROINTESTINAL

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)g

GASTROINTESTINAL

GENITOURINARY

HEMATOLOGY

SOLID TUMOR

Cibisatamab
(CEA x CD3)

(RG7802)

GASTROINTESTINAL

PD-1 x TIM3

(RG7769)

GASTROINTESTINAL

LUNG

MELANOMA

SOLID TUMOR

TLR7 agonist (4)

(RG6115)

GASTROINTESTINAL

HER2 x CD3

(RG6194)

BREAST

GASTROINTESTINAL

SOLID TUMOR

New molecular entity (NME)

(RG6286)

GASTROINTESTINAL

GENITOURINARY

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)g

GASTROINTESTINAL

GENITOURINARY

HEMATOLOGY

SOLID TUMOR

GYNECOLOGIC

HEAD/NECK

HEMATOLOGY

Glofitamab (CD20xCD3)

(RG6026)

HEMATOLOGY

Mosunetuzumab
(CD20 x CD3)

(RG7828)

HEMATOLOGY

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)g

GASTROINTESTINAL

GENITOURINARY

HEMATOLOGY

SOLID TUMOR

CD19 x 4-1BBL

(RG6076)

HEMATOLOGY

Cevostamab (FcRH5 x CD3)

(RG6160)

HEMATOLOGY

Tiragolumab
(anti-TIGIT)

(MTIG7192A, RG6058)

BREAST

SOLID TUMOR

HEMATOLOGY

BCMA x CD16a

(RG6296)h

HEMATOLOGY

New molecular entity (NME)

(RG6234)

HEMATOLOGY

HLA-A2-WT1 x CD3

(RG6007)

HEMATOLOGY

LUNG

PD-1 x TIM3

(RG7769)

GASTROINTESTINAL

LUNG

MELANOMA

SOLID TUMOR

MELANOMA

PD-1 x TIM3

(RG7769)

GASTROINTESTINAL

LUNG

MELANOMA

SOLID TUMOR

TYRP1 x CD3

(RG6232)

 

MELANOMA

PAN TUMOR

SOLID TUMOR

Atezolizumab
(anti-PD-L1 MAb)

(RG7446)g

GASTROINTESTINAL

GENITOURINARY

HEMATOLOGY

SOLID TUMOR

Autogene cevumeran (iNeST)

(RG6180)f

SOLID TUMOR

PD-1 x TIM3

(RG7769)

GASTROINTESTINAL

LUNG

MELANOMA

SOLID TUMOR

Tiragolumab
(anti-TIGIT)

(MTIG7192A, RG6058)

BREAST

SOLID TUMOR

HEMATOLOGY

IL15/IL15Ra-Fc

(RG6323)g

SOLID TUMOR

Inavolisib
(PI3K alpha inhibitor)

(RG6114)

BREAST

SOLID TUMOR

HER2 x CD3

(RG6194)

BREAST

GASTROINTESTINAL

SOLID TUMOR

PD-1 x IL2v

(RG6279)

SOLID TUMOR

PD-1 x LAG3

(RG6139)

SOLID TUMOR

CD25 MAb

(RG6292)

SOLID TUMOR

KRAS G12C

(RG6330)

SOLID TUMOR

Pralsetinib
(RET inhibitor)

(RG6396)

SOLID TUMOR

aDeveloped in collaboration with Array BioPharma. bIgnyta, Inc acquisition. cJoint project with AbbVie. dDeveloped in collaboration with Exelixis. eDeveloped in collaboration with Chugai. fDeveloped in collaboration with BioNTech. gDeveloped in collaboration with Xencor. hDeveloped in collaboration with Affirmed. IDeveloped in collaboration with Blueprint Medicines.
Current as of February 4, 2021. The trial information is taken from ClinicalTrials.gov.

Reference